Androgen Receptor Gene Pathway Upregulation and Radiation Resistance in Oligometastatic Prostate Cancer.
androgen deprivation therapy
androgen receptor
oligometastases
prostate cancer
stereotactic ablative body radiotherapy
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
26 Apr 2022
26 Apr 2022
Historique:
received:
15
03
2022
revised:
09
04
2022
accepted:
24
04
2022
entrez:
14
5
2022
pubmed:
15
5
2022
medline:
18
5
2022
Statut:
epublish
Résumé
Stereotactic ablative body radiotherapy (SABR) is currently used as a salvage intervention for men with oligometastatic prostate cancer (PC), and increasingly so since the results of the Stereotactic Ablative Body Radiotherapy for the Comprehensive Treatment of Oligometastatic Cancers (SABR-COMET) trial reported a significant improvement in overall survival with SABR. The addition of androgen deprivation therapy (ADT) to localised prostate radiotherapy improves survival as it sensitises PC to radiotherapy-induced cell death. The importance of the androgen receptor (AR) gene pathway in the development of resistance to radiotherapy is well established. In this review paper, we will examine the data to determine how we can overcome the upregulation of the AR pathway and suggest a strategy for improving outcomes in men with oligometastatic hormone-sensitive PC.
Identifiants
pubmed: 35563176
pii: ijms23094786
doi: 10.3390/ijms23094786
pmc: PMC9105839
pii:
doi:
Substances chimiques
Androgen Antagonists
0
Receptors, Androgen
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Références
Semin Radiat Oncol. 2022 Jan;32(1):76-81
pubmed: 34861998
Cell. 2009 Jul 23;138(2):245-56
pubmed: 19632176
N Engl J Med. 2019 Jul 11;381(2):121-131
pubmed: 31157964
Endocr Rev. 2004 Apr;25(2):276-308
pubmed: 15082523
Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1179-85
pubmed: 22494583
Diagnostics (Basel). 2020 Jul 31;10(8):
pubmed: 32752137
J Clin Oncol. 1995 Jan;13(1):8-10
pubmed: 7799047
Eur Urol. 2017 Mar;71(3):340-348
pubmed: 27597240
Front Oncol. 2021 Dec 24;11:780507
pubmed: 35004302
BJU Int. 2017 Dec;120(6):815-821
pubmed: 28646594
N Engl J Med. 2009 Jun 11;360(24):2516-27
pubmed: 19516032
N Engl J Med. 1997 Jul 31;337(5):295-300
pubmed: 9233866
Minerva Urol Nefrol. 2018 Oct;70(5):462-478
pubmed: 29664244
Lancet. 2019 May 18;393(10185):2051-2058
pubmed: 30982687
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cancer Discov. 2013 Nov;3(11):1222-4
pubmed: 24203954
Clin Transl Radiat Oncol. 2021 Jun 29;30:1-6
pubmed: 34278008
Int J Mol Sci. 2021 Sep 14;22(18):
pubmed: 34576107
J Clin Oncol. 2018 Feb 10;36(5):446-453
pubmed: 29240541
Int J Radiat Oncol Biol Phys. 2017 Jun 1;98(2):296-303
pubmed: 28463149
Transl Androl Urol. 2018 Jun;7(3):330-340
pubmed: 30050794
Lancet Oncol. 2011 May;12(5):451-9
pubmed: 21440505
Invest New Drugs. 2020 Feb;38(1):181-193
pubmed: 31650446
Cells. 2020 Dec 10;9(12):
pubmed: 33321757
Urology. 2006 Sep;68(3):593-8
pubmed: 16979731
Int J Radiat Oncol Biol Phys. 2007 Nov 1;69(3):646-55
pubmed: 17531401
JAMA. 2004 Aug 18;292(7):821-7
pubmed: 15315996
Prostate. 2018 Jan;78(1):64-75
pubmed: 29134684
Crit Rev Oncog. 2018;23(1-2):39-67
pubmed: 29953367
Cancer Res. 2015 Nov 15;75(22):4688-96
pubmed: 26432404
Lancet. 2022 Jan 29;399(10323):447-460
pubmed: 34953525
JAMA Oncol. 2020 May 1;6(5):650-659
pubmed: 32215577
Mutat Res. 2008 Jul-Aug;659(1-2):49-55
pubmed: 18308619
Int J Mol Sci. 2021 Sep 10;22(18):
pubmed: 34575947
Nat Rev Urol. 2015 Apr;12(4):193-204
pubmed: 25800395
J Clin Oncol. 2015 Feb 1;33(4):332-9
pubmed: 25534388
Cancer Discov. 2013 Nov;3(11):1245-53
pubmed: 24027196
JAMA Oncol. 2021 Jan 01;7(1):92-106
pubmed: 33237270
Nat Rev Clin Oncol. 2020 Dec;17(12):771-781
pubmed: 32843739
Cancer Discov. 2013 Nov;3(11):1254-71
pubmed: 24027197
Front Oncol. 2019 Nov 12;9:1213
pubmed: 31799186
Expert Opin Ther Targets. 2021 May;25(5):329-333
pubmed: 34225539
PLoS One. 2019 Apr 1;14(4):e0214670
pubmed: 30933998
Clin Prostate Cancer. 2003 Jun;2(1):13-4
pubmed: 15046676
Sci Rep. 2019 Jun 20;9(1):8838
pubmed: 31221986
N Engl J Med. 2012 Sep 27;367(13):1187-97
pubmed: 22894553
Cancer Metastasis Rev. 2014 Sep;33(2-3):413-27
pubmed: 24384911
Int J Mol Sci. 2021 Nov 23;22(23):
pubmed: 34884434
J Clin Oncol. 2021 Jan 10;39(2):136-144
pubmed: 33275486
Eur J Nucl Med Mol Imaging. 2021 Feb;48(2):469-476
pubmed: 32617640
Radiother Oncol. 2020 Jul;148:157-166
pubmed: 32388150
Radiat Res. 2010 Dec;174(6):703-11
pubmed: 21128793
J Clin Oncol. 2020 Sep 1;38(25):2830-2838
pubmed: 32484754
Lancet Oncol. 2016 Aug;17(8):1047-1060
pubmed: 27339115
Vitam Horm. 1999;55:309-52
pubmed: 9949684
Science. 2009 May 8;324(5928):787-90
pubmed: 19359544
Front Mol Biosci. 2014 Nov 17;1:24
pubmed: 25988165